Pfizer India Ltd Q1FY26 – “₹670 Cr Sales, ₹192 Cr PAT, 35x P/E: Vaccines, Cough Syrup, and GST Notices – The Big Pharma Multinational with Small India Growth”
1. At a Glance
Pfizer India is that posh kid in class: branded parent (Pfizer Inc.), massive portfolio (125+ products), and a Goa beach factory cranking 3.6 billion tablets a year. Yet growth? Slower than your family WhatsApp downloads. Q1FY26 delivered ₹670 Cr revenue, ₹192 Cr PAT, and an EPS of ₹41.9, while stock trades at a juicy P/E of 35x. Margins are fat (33% OPM), but sales growth is a tragic 1% CAGR over 5 years. Basically: the business runs like a Swiss watch, but in slow motion.
2. Introduction
If you’ve ever had Gelusil after overeating biryani or coughed your lungs out till Corex rescued you, chances are you’ve indirectly funded Pfizer India. This subsidiary of global giant Pfizer Inc. is the 3rd largest MNC pharma player in India.
But unlike its global daddy, which moonlights as the savior of humanity with mRNA vaccines, the India arm often looks like the forgotten cousin—managing internal medicine, hospital injectables, and one flagship vaccine (Prevenar 13). In 2025, they even launched the 20-valent PCV vaccine (because 13 valent was too mainstream).
Here’s the kicker: despite elite brand equity, they’ve faced recalls (Magnex, Zosyn, Magnamycin in 2023), NLEM price cuts, and GST tax notices—turning their revenue chart into a rollercoaster. Profit is cushioned by fat other income (₹370 Cr in FY25), making P&L look healthier than it really is.
So, is Pfizer India a safe prescription for long-term stability or just an overpriced tablet in the pharma shelf?
3. Business Model – WTF Do They Even Do?
Pfizer India’s business is a cocktail of:
Vaccines: Flagship Prevenar 13 for pneumococcal disease and the new PCV20 launch. Dominates private vaccine market with 65% value share.
Hospital Anti-infectives: Zavicefta, Meronem, Magnex—sold to hospitals for critical care.
Inflammation & Immunology: Enbrel, Betrecep for rheumatoid arthritis and ulcerative colitis.
Manufacturing is Goa-based (3.6 bn tablets annually), supplemented with 18 contract manufacturers handling another 1.9 bn units. 70% of production is local, making Pfizer India surprisingly “Atmanirbhar” for an MNC.
Distribution muscle: touches 300M patients yearly, via 2.5 lakh pharmacies, 1,800 hospitals, and 2 lakh healthcare providers. Basically, their sales reps could outnumber your local kirana chain.
